Recombinant polypeptide and application thereof
By modifying the E2 domain of the Sindbis virus and combining it with targeting components such as VHH antibody, the fusion efficiency of extracellular vesicles with target cells was improved, solving the instability and off-target effects of EVs in targeted drug delivery, and achieving more efficient drug delivery and therapeutic effects.
Patent Information
- Application Number
- CN202310588172.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-26
AI Technical Summary
In the existing technology, extracellular vesicles (EVs) suffer from instability, off-target effects, and low target cell fusion efficiency when delivering drug molecules to specific cell types, resulting in poor therapeutic effects.
By modifying the E2 domain of the Sindbis virus to eliminate its cell recognition function, and by combining it with receptor ligands, antibodies, or their functional fragments such as VHH antibodies, the fusion of EVs with target cell membranes is promoted, thereby improving targeting and fusion efficiency.
It significantly improves the delivery efficiency of drug molecules within target cells and the therapeutic effect, especially in cancer cells, enhancing the therapeutic efficacy of drugs.
Smart Images

Figure CN119019565A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of molecule delivery, and more particularly to a recombinant polypeptide for delivering molecules to cells in a targeted manner and a use thereof. Background Art
[0002] The targeted delivery of therapeutic molecules within biological systems is an important part of disease treatment. Studies have shown that cell-derived extracellular vesicles (EVs) can be used as drug carriers to deliver drugs. As particles encapsulated by lipid bilayers secreted by cells, they have low immunogenicity compared to micelles, liposomes, and polymer nanoparticles. EVs can also fuse with receptor cell membranes, avoid lysosomal engulfment, and deliver drugs directly to the cytoplasm, thereby significantly improving the drug delivery efficiency. However, the instability, off-target effects before reaching the target cells, and the efficiency of fusion with target cells directly limit the application of this delivery method, and the targeted delivery of drug molecules to specific cell types remains a challenge.
[0003] Therefore, it is desirable to provide a stable targeted therapeutic delivery vehicle and method that treats only target cells. Summary of the invention
[0004] In a first aspect, the present invention provides a recombinant polypeptide for directing an extracellular vesicle (EV) to at least one target cell, the recombinant polypeptide comprising:
[0005] - at least one targeting moiety for directing said extracellular vesicle to said at least one target molecule expressed by said at least one target cell,
[0006] - a polypeptide for fusing the extracellular vesicle with the cell membrane of a target cell.
[0007] As a preferred embodiment, the polypeptide used to fuse the extracellular vesicle with the cell membrane of the target cell comes from a modified Sindbis virus, and the virus modification consists in removing or completely replacing the amino acids at positions 65-74, 66-75, 67-76, 68-77, 69-78, 70-79 or 71-80 of the Sindbis virus E2 domain.
[0008] As a preferred embodiment, the amino acids at positions 65-74, 66-75, 67-76, 68-77, 69-78, 70-79 or 71-80 of the Sindbis virus E2 domain are replaced with MYPYDVPDYA.
[0009] As a preferred embodiment, the at least one target cell comprises a mammalian cell.
[0010] As a preferred embodiment, the mammalian cells are human cells.
[0011] As a preferred embodiment, the at least one target cell is a tumor cell, a tumor stromal cell or an immune cell.
[0012] As a preferred embodiment, the at least one target molecule is a cell surface marker or a cell surface receptor.
[0013] As a preferred embodiment, the cell surface marker or cell surface receptor is a tumor-associated antigen.
[0014] As a preferred embodiment, tumor-associated antigens include but are not limited to Her2, DEC205, CLEC9A, CEACAM5, CTLA4, CD3, CD7, CD11c, CD19, CD20, CD22, CD40, CD44, CD206, EGFR, EGFRvIII, fibroblast activation protein (FAP), CA9, MMP-2, PD-L1, SIRPa, Trop2, GPC1, GPC3, cMET, BCMA, VEGFR, and Cladin18.2.
[0015] As a preferred embodiment, the at least one targeting moiety comprises a receptor ligand, an antibody or a functional fragment thereof, such as scFv, VHH, a single domain antibody or a DARPin.
[0016] As a preferred embodiment, the antibody is a single domain antibody.
[0017] As a preferred embodiment, the antibody is a VHH antibody.
[0018] As a preferred embodiment, the antibody is a humanized antibody.
[0019] As a preferred embodiment, the at least one targeting moiety comprises an anti-Her2 VHH antibody, an anti-DEC205 VHH antibody, an anti-CLEC9A VHH antibody, an anti-CEACAM5 VHH antibody, an anti-CTLA4 VHH antibody, an anti-CD3 VHH antibody, an anti-CD7 VHH antibody, an anti-CD11c VHH antibody, an anti-CD19 VHH antibody, an anti-CD20 VHH antibody, an anti-CD22 VHH antibody, an anti-CD40 VHH antibody, an anti-CD44 VHH antibody, an anti-CD206 VHH antibody, H antibody, VHH antibody against EGFR, VHH antibody against EGFRvIII, VHH antibody against fibroblast activation protein (FAP), VHH antibody against CA9, VHH antibody against MMP-2, VHH antibody against PD-L1, VHH antibody against SIRPa, VHH antibody against Trop2, VHH antibody against GPC1, VHH antibody against GPC3, VHH antibody against cMET, VHH antibody against BCMA, VHH antibody against VEGFR, and VHH antibody against Cladin18.2.
[0020] The second aspect of the present invention provides a nucleic acid molecule encoding the aforementioned recombinant polypeptide.
[0021] The third aspect of the present invention provides a vector comprising the aforementioned nucleic acid molecule.
[0022] The fourth aspect of the present invention provides a host cell comprising the aforementioned nucleic acid molecule or the aforementioned vector.
[0023] As a preferred embodiment, the host cells include prokaryotic cells, eukaryotic cells, yeast cells, insect cells, mammalian cells and modified mammalian cells.
[0024] As a preferred embodiment, the host cell includes B cells, T cells, dendritic cells, macrophages or neutrophils or CAR-T cells.
[0025] As a preferred embodiment, the host cell further comprises an EV cargo molecule.
[0026] As a preferred embodiment, the EV cargo molecule includes a nucleic acid or a polypeptide or a chemotherapeutic drug.
[0027] As a preferred embodiment, the nucleic acid includes mRNA, miRNA or shRNA.
[0028] The fifth aspect of the present invention provides a targeted extracellular vesicle (targeted EV), which comprises a modified Sindbis virus, wherein the amino acids 65-74, 66-75, 67-76, 68-77, 69-78, 70-79 or 71-80 of the E2 domain of the Sindbis virus are replaced with MYPYDVPDYA.
[0029] As a preferred embodiment, the amino acid sequence of the modified Sindbis virus is shown in NO:1.
[0030] As a preferred embodiment, the targeted extracellular vesicle (targeted EV) also contains a single domain antibody as shown in NO:3.
[0031] As a preferred embodiment, it comprises the aforementioned recombinant polypeptide.
[0032] As a preferred embodiment, the present invention provides a targeted extracellular vesicle (targeted EV), comprising a polypeptide having an amino acid sequence as shown in NO: 1 and a single domain antibody having an amino acid sequence as shown in NO: 3.
[0033] As a preferred embodiment, the targeted extracellular vesicles (targeted EVs) contain payload drugs.
[0034] As a preferred embodiment, the targeted extracellular vesicles (targeted EVs) contain cargo molecules.
[0035] The payload drug includes a nucleic acid or a polypeptide or a chemotherapeutic drug. The cargo molecule includes a nucleic acid or a polypeptide or a chemotherapeutic drug. The payload drug or cargo molecule is encapsulated in a targeted extracellular vesicle for treating a disease. The disease includes but is not limited to tumors and autoimmune diseases.
[0036] In a preferred embodiment, the targeted extracellular vesicles (targeted EVs) are exosomes, microvesicles, extracellular granules, and apoptotic bodies.
[0037] The sixth aspect of the present invention provides a composition comprising the aforementioned nucleic acid, the aforementioned vector, the aforementioned targeted EV; and a pharmaceutically acceptable excipient, diluent or carrier.
[0038] A seventh aspect of the present invention provides a method for binding a targeting moiety to a target molecule of a target cell, the method comprising contacting the target cell with the aforementioned targeted extracellular vesicle (targeted EV).
[0039] The eighth aspect of the present invention provides the use of the targeted extracellular vesicles (targeted EVs) for delivering drugs to target cells.
[0040] Beneficial Effects
[0041] Compared with the prior art, the beneficial effects of the present invention are:
[0042] The present invention transforms the E2 domain of the Sindbis virus so that the cell recognition (binding) function of the E2 domain is lost, and the modified virus is used as a protein for promoting membrane fusion between CNV and target cells, and receptor ligands, antibodies or their functional fragments, single domain antibodies or DARPin are used as molecules to provide targeting for CNV, and the targeted molecules bind to surface antigens of target cells such as cancer cells, and the protein promoting membrane fusion promotes the fusion of the cytoplasmic membrane of CNV and the target cell, so that the drug molecules carried inside the CNV exert excellent cancer treatment effects. Compared with CNV that does not express proteins that promote membrane fusion, the modified CNV of the present invention greatly improves the membrane fusion efficiency and further improves the drug treatment effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] In order to more clearly illustrate the technical solution of the present application, the drawings required for use in the embodiments are briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without any creative work.
[0044] Figure 1 Schematic diagram of the modified extracellular vesicle of the present invention; wherein: 1. Anti-Her2 VHH; 2. Polypeptide A; 3. CNV;
[0045] Figure 2 Schematic diagram of the Sindbis virus E2 domain. DETAILED DESCRIPTION
[0046] The present invention is further described in detail below in conjunction with embodiments so that those skilled in the art can implement the invention with reference to the description.
[0047] Recombinant Peptide
[0048] A recombinant polypeptide for directing an extracellular vesicle (EV) to at least one target cell, the recombinant polypeptide comprising:
[0049] - at least one targeting moiety for directing said EV to said at least one target molecule expressed by said at least one target cell,
[0050] - A polypeptide for fusing said EV with the cell membrane of a target cell.
[0051] In one embodiment, the polypeptide used to fuse the EV with the cell membrane of the target cell is derived from the full-length sequence of the modified Sindbis virus, and the virus modification consists in removing or completely replacing the amino acids at positions 65-74, or 66-75, 67-76, 68-77, 69-78, 70-79, and 71-80 of the E2 domain of the Sindbis virus.
[0052] In one embodiment, the amino acids at positions 65-74, or 66-75, 67-76, 68-77, 69-78, 70-79, or 71-80 of the E2 domain of the Sindbis virus are replaced with MYPYDVPDYA.
[0053] In one embodiment, wherein the at least one target cell comprises a mammalian cell.
[0054] In one embodiment, the mammalian cell is a human cell.
[0055] In one embodiment, the at least one target cell is a tumor cell, a tumor stromal cell or an immune cell.
[0056] In one embodiment, the at least one target molecule is a cell surface marker or a cell surface receptor.
[0057] In one embodiment, the cell surface marker or cell surface receptor is a tumor associated antigen.
[0058] In one embodiment, tumor-associated antigens include Her2, DEC205, CLEC9A, CEACAM5, CTLA4, CD3, CD7, CD11c, CD19, CD20, CD22, CD40, CD44, CD206, EGFR, EGFRvIII, fibroblast activation protein (FAP), CA9, MMP-2, PD-L1, SIRPa, Trop2, GPC1, GPC3, cMET, BCMA, VEGFR, and Cladin18.2.
[0059] In one embodiment, the at least one targeting moiety comprises a receptor ligand, an antibody or a functional fragment thereof, a single domain antibody (VHH) or a DARPin.
[0060] In one embodiment, wherein the antibody is a single domain antibody (VHH).
[0061] In one embodiment, the antibody is a humanized antibody.
[0062] In one embodiment, the at least one targeting moiety comprises an anti-Her2 VHH antibody, an anti-DEC205 VHH antibody, an anti-CLEC9A VHH antibody, an anti-CEACAM5 VHH antibody, an anti-CTLA4 VHH antibody, an anti-CD3 VHH antibody, an anti-CD7 VHH antibody, an anti-CD11c VHH antibody, an anti-CD19 VHH antibody, an anti-CD20 VHH antibody, an anti-CD22 VHH antibody, an anti-CD40 VHH antibody, an anti-CD44 VHH antibody, an anti-CD206 VHH antibody. Antibodies, VHH antibodies against EGFR, VHH antibodies against EGFRvIII, VHH antibodies against fibroblast activation protein (FAP), VHH antibodies against CA9, VHH antibodies against MMP-2, VHH antibodies against PD-L1, VHH antibodies against SIRPa, VHH antibodies against Trop2, VHH antibodies against GPC1, VHH antibodies against GPC3, VHH antibodies against cMET, VHH antibodies against BCMA, VHH antibodies against VEGFR, and VHH antibodies against Cladin18.2.
[0063] Nucleic acid molecules
[0064] The second aspect of the present invention provides a nucleic acid molecule encoding the aforementioned recombinant polypeptide.
[0065] Carrier
[0066] The third aspect of the present invention provides a vector comprising the aforementioned nucleic acid molecule.
[0067] Host cells
[0068] In one aspect, a host cell is provided, comprising the aforementioned nucleic acid and the aforementioned vector.
[0069] In one embodiment, the host cell includes prokaryotic cells, eukaryotic cells, yeast cells, insect cells, mammalian cells and modified mammalian cells.
[0070] As a preferred embodiment, the host cell includes B cells, T cells, dendritic cells, macrophages or neutrophils or CAR-T cells.
[0071] EV cargo molecules
[0072] As a preferred embodiment, the host cell further comprises an EV cargo molecule.
[0073] As a preferred embodiment, the EV cargo molecule includes a nucleic acid or a polypeptide or a chemotherapeutic drug.
[0074] As a preferred embodiment, the nucleic acid includes mRNA, miRNA or shRNA.
[0075] The fifth aspect of the present invention provides a targeted extracellular vesicle (targeted EV), which comprises the aforementioned recombinant polypeptide.
[0076] As a preferred embodiment, the targeted EV contains a payload drug.
[0077] As a preferred embodiment, the targeted EV contains cargo molecules.
[0078] As a preferred embodiment, the targeted EV contains a modified Sindbis virus, and the amino acids 65-74, or 66-75, 67-76, 68-77, 69-78, 70-79, and 71-80 of the E2 domain of the Sindbis virus are replaced with MYPYDVPDYA.
[0079] As a preferred embodiment, the targeted EV contains a polypeptide having an amino acid sequence as shown in NO: 1 and a single domain antibody having an amino acid sequence as shown in NO: 3.
[0080] In a preferred embodiment, EVs are exosomes, microvesicles, extranuclear granules, or apoptotic bodies.
[0081] The sixth aspect of the present invention provides a composition comprising the aforementioned nucleic acid, the aforementioned vector, the aforementioned targeted EV; and a pharmaceutically acceptable excipient, diluent or carrier.
[0082] A seventh aspect of the present invention provides a method for binding a targeting moiety to a target molecule of a target cell, the method comprising contacting the target cell with the aforementioned targeting EV.
[0083] The eighth aspect of the present invention provides the use of the targeted EV for delivering drugs to target cells.
[0084] Production method
[0085] In one embodiment, a method for producing a targeted EV is provided, wherein the method comprises expressing a nucleic acid as defined herein in a cell, or culturing a host cell as defined herein to produce a targeted EV; and collecting the targeted EV. The cell includes any mammalian cell or modified mammalian cell.
[0086] Definitions and Examples
[0087] The following definitions are provided to facilitate understanding of the terms used herein.
[0088] "Extracellular vesicles" (EVs): are cell-derived membrane structures, including exosomes, microvesicles, virus-like particles, macrovesicles, oncosomes, nanovesicles, and apoptotic bodies. These extracellular vesicles are usually classified based on their size, specific markers, cellular origin, and biogenesis process. Exosomes are 30-160 nm vesicles of endosomal origin released from cells when the multivesicular body (MVB) membrane fuses with the plasma membrane. Exosomes are produced by every cell type, and their release can be induced by a variety of stimuli, including stress, hypoxia, cell death, and viral infection. Classical microvesicles (also called microparticles) are 100 nm-1 μm vesicles released from cells by shedding of the plasma membrane. Cancer cells can also secrete larger microvesicles (>1 μm) called oncosomes, which differ from classical microvesicles only in size. Like exosomes, microvesicle release can be induced by stress and viral infection, and their The contents are heterogeneous. Apoptotic bodies are large EVs that are released from apoptotic cells by blebbing and range in size from 200 nm to 5 μm. These phosphatidylserine and annexin V-coated EVs contain cytoplasmic contents from dying cells. Traditionally, EVs that precipitate at 100,000 g are called exosomes, but in fact, this precipitate contains a combination of microvesicles and exosomes. Although their biogenesis pathways are different, exosomes and microvesicles have many similarities and are difficult to distinguish from each other once released from cells. Recently, the International Society for Extracellular Vesicles suggested that the term small EV (sEV) should be used for particles less than 200 nm in size, while the term large EV (lEV) should be used for particles greater than 200 nm in size. Among EVs, there is a type of nanosized vesicle (cell-derived nanovesicles, CNV) that resembles nEVs in appearance and structure.
[0089] Table 1: Examples of proteins with EV membrane binding domains
[0090] Protein Source sequence Sindbis virus (SINV) genus The modified full-length sequence of the virus with partial amino acid deletion or substitution in the structural domain of the virus E2
[0091] like Figure 2 As shown, the E2 domain of Sindbis virus was modified in such a way that the amino acids at positions 65-74, 66-75, 67-76, 68-77, 69-78, 70-79, and 71-80 of the domain were replaced with MYPYDVPDYA (HA tag). The modified recombinant protein was named polypeptide A and used as the membrane fusion protein of CNV.
[0092] "Targeted EV" is used synonymously herein to refer to an EV comprising a recombinant polypeptide as defined herein and thus having an engineered affinity for a target molecule (provided by the targeting moiety).
[0093] "Targeting moiety" means a molecule that is capable of binding to a target molecule with sufficient affinity and specificity to enable targeting of EVs to target cells expressing the target molecule. Non-limiting examples of targeting moieties include antibodies, functional fragments thereof, engineered fragments thereof, ligands (which target receptors), designed ankyrin repeat proteins (DARPins) (which bind to target proteins), and domains that mediate specific protein-protein interactions.
[0094] In one embodiment, tumor-associated antigens include Her2, DEC205, CLEC9A, CEACAM5, CTLA4, CD3, CD7, CD11c, CD19, CD20, CD22, CD40, CD44, CD206, EGFR, EGFRvIII, fibroblast activation protein (FAP), CA9, MMP-2, PD-L1, SIRPa, Trop2, GPC1, GPC3, cMET, BCMA, VEGFR, and Cladin18.2.
[0095] Table 2: Exemplary targeting moieties
[0096] name describe application VHH against Her2 Targeting Her2 Delivering therapeutic drugs to tumor cells VHH against DEC205 Targeting DEC205 Delivering therapeutic drugs to tumor cells VHH against CLEC9A Targeting CLEC9A Delivering therapeutic drugs to tumor cells VHH against CEACAM5 Targeting CEACAM5 Delivering therapeutic drugs to tumor cells Anti-CTLA4 VHH Targeting CTLA4 Delivering therapeutic drugs to tumor cells VHH against CD3 Targeting CD3 Delivering therapeutic drugs to tumor cells VHH against CD7 Targeting CD7 Delivering therapeutic drugs to tumor cells VHH against CD11c Targeting CD11c Delivering therapeutic drugs to tumor cells VHH against CD19 Targeting CD19 Delivering therapeutic drugs to tumor cells VHH against Trop2 Targeting Trop2 Delivering therapeutic drugs to tumor cells VHH against GPC1 Targeting GPC1 Delivering therapeutic drugs to tumor cells VHH against GPC3 Targeting GPC3 Delivering therapeutic drugs to tumor cells VHH against cMET Targeting cMET Delivering therapeutic drugs to tumor cells Anti-BCMA VHH Targeting BCMA Delivering therapeutic drugs to tumor cells Anti-VEGFR VHH Targeting VEGFR Delivering therapeutic drugs to tumor cells VHH against Cladin18.2 Targeting Cladin18.2 Delivering therapeutic drugs to tumor cells
[0097] "Single domain antibodies" (sdAb), also called nanobodies, like VHH, are antibody fragments composed of a single monomeric variable antibody domain. Like a complete antibody, it is able to selectively bind to a specific antigen. With a molecular weight of only 12-15 kDa, single domain antibodies are much smaller than ordinary antibodies composed of two heavy chains and two light chains. sdABs are produced by immunizing dromedary camels, llamas, alpacas, or sharks, or can be engineered from ordinary IgGs with four chains.
[0098] The term "functional fragment" means a portion of an antibody that retains the paratope (comprising the complementarity determining regions or CDRs) and is capable of binding to the same target molecule as the parent antibody from which it is derived. Examples include Fab and F(ab')2 fragments.
[0099] The term "engineered fragment" refers to a recombinant polypeptide derived from a parent antibody and retaining the paratope, and therefore capable of binding to the same target molecule as the parent antibody. An example is a single-chain variable fragment (VHH), which is a fusion protein of the variable regions of the heavy chain (VH) and light chain (VL) of an immunoglobulin, connected by a short linker peptide of typically 10 to about 25 amino acids.
[0100] The term "DARPin" is a repeating protein containing several repeating domains (usually 4 to 6 repeats) of typically 33 amino acids. DARPins can be selected and used as alternative scaffolds for specific targeting because they can bind their target antigens with high affinity and specificity. A key advantage of using DARPins compared to monoclonal antibodies is that DARPins are typically of low molecular weight, containing 40 to 100 amino acid residues. For example, HER2 is frequently overexpressed in breast cancer cells. DARPins that bind to the extracellular domain of HER2 can be selected and used to direct therapeutic EVs to malignant cells expressing HER2.
[0101] The term "target molecule" means a molecule to which a targeting moiety binds. Such a molecule may be a cell surface molecule, for example, a polypeptide, lipid or polysaccharide that can be specifically bound by a targeting moiety.
[0102] The term "target cell" means a cell that expresses a target molecule that is bound by a targeting moiety and to which a payload (if applicable) and / or cargo (if applicable) is directed.
[0103] "Tumor-associated antigen" (TAA) means any immunogen that is associated with tumor cells and is absent or less abundant in healthy cells or corresponding healthy cells (depending on the application and requirements). For example, in the context of an organism, a tumor-associated antigen may be unique to a tumor cell. A TAA may be, for example, a tumor-specific mutation, an aberrantly spliced protein, a carcinoembryonic antigen, or an endogenous retroviral protein. A TAA may be a neoantigen that contains a new epitope. A neoantigen is a previously unrecognized antigen that has not been previously identified.
[0104] Newly formed (non-self) antigens that are recognized by the immune system and may result, for example, from tumor mutations.
[0105] The terms "payload" and "cargo" are used here differently. The former is part of the recombinant polypeptide, while "cargo" is intended to be a separate molecule carried in the EV.
[0106] A “payload” may be an “EV payload polypeptide” or an “EV therapeutic payload polypeptide”.
[0107] By "EV payload polypeptide" is meant any polypeptide that is part of the recombinant polypeptide itself and is therefore encoded by the same nucleic acid molecule. EV payload polypeptides include any polypeptide that would be desirable for EV loading or EV-mediated targeting or delivery.
[0108] By "EV therapeutic payload polypeptide" is meant a therapeutic polypeptide that is part of the recombinant polypeptide itself and thus will be co-encoded by the same nucleic acid molecule. Classes of payloads include (but are not limited to) cytotoxic molecules (e.g., GZMB variants, diphtheria toxin, pe38 (domain from Pseudomonas exotoxin A), or TRAIL), immune reprogramming molecules (e.g., STING or ERAdP pathway activators such as bacterial cyclases), enzymes, nucleotide binding domains, and antigens (such as tumor antigens or antigens from infectious pathogens such as dengue virus, malaria, or rotavirus).
[0109] Example 1: Construction of Targeted CNV
[0110] 1. Construct a plasmid (use genetic engineering to synthesize the nucleic acid sequence encoding polypeptide A and the nucleic acid sequence encoding anti-Her2 VHH into a universal plasmid template, or synthesize the nucleic acid sequence containing the recombinant protein encoding polypeptide A and anti-Her2 VHH (nanobody) into a universal plasmid vector.
[0111] Among them, the amino acid sequence numbering of the modified membrane fusion protein from the sindbis virus is shown in SEQ ID NO: 1 (named as polypeptide A), and the amino acid sequence numbering of the E2 domain of the modified sindbis virus is shown in SEQ ID NO: 2.
[0112] The nucleic acid sequence encoding the anti-Her2 VHH antibody is numbered as shown in SEQ ID NO: 3. The amino acid sequence of the anti-Her2 VHH antibody is numbered as shown in SEQ ID NO: 4.
[0113] Table 3 Amino acid sequences of modified viruses
[0114]
[0115]
[0116] Schematic diagram of the E2 domain after virus modification Figure 2 shown.
[0117] Table 4 Nucleic acid sequences encoding anti-Her2 VHH antibodies
[0118]
[0119] Table 5 Amino acid sequences encoding VHH antibodies
[0120]
[0121] 2. HEK293 cells are used as donors. Subsequently, the plasmid containing the nucleic acid sequence encoding polypeptide A and the recombinant protein of anti-Her2 VHH in step 1) is transfected into HEK293 cells to express membrane-bound anti-Her2 VHH and membrane fusion protein polypeptide A, and targeted CNV is generated and collected. The final constructed CNV has the functions of targeting and membrane fusion, the targeting is provided by the anti-Her2 VHH antibody, and the membrane fusion function is provided by the membrane fusion protein polypeptide A. The final generated CNV is named B-CNV (i.e., targeted CNV).
[0122] 3. CNV and A-CNV were constructed as controls at the same time. CNV is an unmodified vesicle produced by wild-type HEK293, and A-CNV is an A-CNV produced by HEK293 without anti-Her2 VHH (the preparation method is: the nucleic acid sequence encoding membrane fusion protein polypeptide A is synthesized into a universal plasmid template by genetic engineering, and then transfected into HEK293 cells). It has been verified that CNV, A-CNV and modified B-CNV all contain classic EV markers, including membrane-bound protein CD81 and cytoplasmic protein TSG101.
[0123] 4. This step investigates whether the modified B-CNV can fuse to the membrane of SK-BK-3 cells expressing Her2, as follows: SK-BK-3 cells were co-cultured with B-CNV for 30 minutes, which is sufficient for Her2 / anti-Her2 VHH to interact. The signal of the HA tag was detected from the membrane protein extracted from the treated SK-BK-3 cells. The E2 domain of the modified virus (e.g. Figure 2 ). The band intensity of the HA tag increased with the increase in the number of modified B-CNVs. Based on the signal intensity, semi-quantitative data showed that the average fusion efficiency of the membrane fusion protein polypeptide A molecule fused to the SK-BK-3 cells in each group was 62%. The above results confirm that the modified B-CNV can indeed effectively bind to and fuse to the plasma membrane of SK-BK-3 cells through the anti-Her2 VHH antibody. And characterization proves that B-CNV can attach and fuse to the target cell plasma membrane within 20 minutes. CNV hardly attaches to the SK-BK-3 cell membrane; A-CNV adheres to the SK-BK-3 cell membrane through anti-Her2 VHH, but does not trigger membrane fusion; experiments confirm that only the modified B-CNV binds and fuses to the SK-BK-3 cell plasma membrane.
[0124] Example 2
[0125] BT-474 cells expressing Her2 were further incubated, and after 30 minutes of co-culture. Again, CNV barely attached to the BT-474 cell membrane; A-CNV adhered to the BT-474 cell membrane through anti-Her2 VHH, but did not trigger membrane fusion; only the modified B-CNV bound and fused to the BT-474 cell plasma membrane. Fluorescence resonance energy transfer assays confirmed the fusion between B-CNV and BT-474 cell membranes, with an average fusion efficiency of 68% within 30 minutes under pH 5-6 conditions.
[0126] Example 3: CNV drug loading
[0127] Paclitaxel was loaded into CNV, A-CNV, and B-CNV by ultrasonic treatment, and then tumor cell inhibition experiments were performed. Compared with the free paclitaxel group, CNV group, and A-CNV group, the therapeutic effect of the paclitaxel-loaded B-CNV group was significantly improved by 26.8 times, 5 times, and 2.2 times. Compared with other groups, the drug-loaded B-CNV group was able to cause significant tumor tissue damage, indicating an enhanced therapeutic effect.
[0128] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A recombinant polypeptide for directing an extracellular vesicle (EV) to at least one target cell, characterized in that: The recombinant polypeptide comprises: - at least one targeting moiety for directing said extracellular vesicle to said at least one target molecule expressed by said at least one target cell, - a polypeptide for fusing the extracellular vesicle with the cell membrane of a target cell.
2. The recombinant polypeptide according to claim 1, characterized in that: The polypeptide used to fuse the extracellular vesicle with the cell membrane of the target cell comes from the full-length sequence of the modified Sindbis virus, and the virus modification is to remove or completely replace the amino acids at positions 65-74, 66-75, 67-76, 68-77, 69-78, 70-79 or 71-80 of the Sindbis virus E2 domain.
3. The recombinant polypeptide according to claim 2, characterized in that: The amino acids 65-74, 66-75, 67-76, 68-77, 69-78, 70-79 or 71-80 of the E2 domain of the Sindbis virus are replaced with MYPYDVPDYA.
4. The recombinant polypeptide according to claim 3, characterized in that: Wherein the at least one target molecule is a cell surface marker or a cell surface receptor.
5. The recombinant polypeptide according to any one of claims 1 to 4, characterized in that: The at least one targeting moiety comprises a receptor ligand, an antibody or a functional fragment thereof, a single domain antibody VHH or a DARPin.
6. A nucleic acid molecule, characterized in that: It encodes a recombinant polypeptide as defined in any one of claims 1 to 5.
7. A carrier, characterized in that: It comprises the nucleic acid molecule according to claim 6.
8. A host cell, characterized in that: It comprises the nucleic acid molecule according to claim 6 and the vector according to claim 7.
9. A method for targeting extracellular vesicles, characterized in that: It comprises a modified Sindbis virus, wherein the amino acids at positions 65-74, or positions 66-75, 67-76, 68-77, 69-78, 70-79, and 71-80 of the E2 domain of the Sindbis virus are replaced with MYPYDVPDYA.
10. A method for targeting extracellular vesicles, characterized in that: It comprises a modified Sindbis virus, and the amino acid sequence of the modified Sindbis virus is shown in NO:
1.
11. The targeted extracellular vesicle according to claim 10, characterized in that: It also contains the single domain antibody sequence as shown in NO:
3.
12. A method for targeting extracellular vesicles, characterized in that: It comprises the recombinant polypeptide according to any one of claims 1 to 5.
13. The targeted extracellular vesicle according to any one of claims 9 to 11, characterized in that: Its targeted extracellular vesicles contain the drug payload.
14. The targeted extracellular vesicle according to any one of claims 9 to 12, characterized in that: It targets extracellular vesicles containing cargo molecules.
15. A composition comprising the nucleic acid molecule of claim 6, the vector of claim 7, or the targeted extracellular vesicle of any one of claims 9-14; and a pharmaceutically acceptable excipient, diluent or carrier.
16. A method for binding a targeting moiety to a target molecule of a target cell, characterized in that: The method comprises contacting the target cell with the targeted extracellular vesicle of any one of claims 9-14.
17. Use of the targeted extracellular vesicle according to any one of claims 9 to 14 for delivering drugs to target cells.
